Capricor Therapeutics, Inc.

CAPR Healthcare Biotechnology

Capricor Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $22.3 million, down 11.5% from fiscal 2023. In the quarter to June 2026, revenue fell 7.92%, EPS fell 22.8% and free cash flow fell 72.9%, each against the same quarter a year earlier.

6.88 0.59 −7.90%
Market cap
$434.3M
P/E
0.0×
Fwd P/E
−13.2×
Dividend yield
—
F-score
4/9
Altman Z
10.32
Beneish M
−2.61
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Quick Ratio
3.50 8.88 8.28 7.22
Current Ratio
3.59 9.01 8.42 7.35
Net Debt/EBITDA
3.82 11.10 7.61 5.50
Debt/Assets
0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00
Asset Turnover
0.00 0.00 0.00 0.00
Operating CF/Net income
0.80 0.78 0.86 0.77
Capex/Depreciation
(8.10) 508.40 (61.06) 17.54
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00%
Free Cash Flow Yield
— — — —
Revenue per Share
0.00 0.00 0.00 0.00
Operating CF per Share
(0.43) (0.51) (0.51) (0.54)
Capex per Share
(0.09) 5.50 (0.19) (0.10)
Free Cash Flow per Share
(0.52) 4.99 (0.70) (0.64)
Cash per Share
2.16 6.84 4.85 4.11
Shareholders Equity per Share
1.83 6.58 4.85 4.25
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
1.83 6.58 4.85 4.25
Free Cash Flow
(23.70) 231.90 (40.00) (37.29)
Working Capital
72.80 287.10 249.45 209.17
Capital Expenditures
(4.01) 255.47 (10.75) (5.81)
Net Current Asset Value
58.38 272.78 235.51 119.61
EV/EBIT
— — — —
Capex to Sales
0.00 0.00 0.00 0.00
Other line items
Average Receivables
0.23 5.21 — —
Average Payables
4.63 2.47 4.59 3.95
Average Assets
109.69 263.22 240.02 251.15
Average Common Equity
76.07 225.63 203.17 175.60

Fold the line items

Columns are period end dates